Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Maryland for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Maryland only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Maryland (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Mei Tang (NPI 1457495483)

Field	Value
Entity Type	Individual
Organization	Mei Tang
Address	6569 N Charles St Ste 201
City	Baltimore
State	MD
ZIP	21204
Taxonomy	Medical Oncology Physician
NPI Enumerated	February 15, 2007

Payer Source	Total Paid
Medicare	$6.9M
Medicaid	$0

Key Findings

Practice profile: The provider’s Medicare code mix is dominated by high‑cost oncology infusions and supportive biologics — leading codes include J9271 (pembrolizumab), J9144 (daratumumab), J9299 (nivolumab) alongside high-volume chemotherapy administration codes (96413, 96417, 96415). This pattern is consistent with an outpatient medical oncology infusion practice that administers monoclonal antibodies, immune therapies, and associated procedural chemotherapy services rather than primary care or inpatient work.

Revenue concentration: The top three Medicare codes by revenue account for 63.5% of this provider’s total Medicare revenue, with J9271 alone generating $2.7M (39.6% of Medicare revenue). The next two top drivers are J9144 at $855K (12.5%) and J9299 at $777.5K (11.4%), indicating material revenue dependence on a small set of high‑value oncology agents.

Payer mix: This provider reports $6.9M in total Medicare revenue and has no Medicaid billing on file, making the practice effectively single‑payer (Medicare) in the billed data. The absence of Medicaid activity suggests limited public‑program diversification in the available claims records.

National competitive standing — flagship code: J9271 volume is exceptionally large (67.6K claims) and ranks #7 of 1841 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code), signaling a nationally significant footprint for pembrolizumab administration compared with peers.

National competitive standing — additional agents and biosimilars: Other high‑revenue drugs show above‑typical national standing but lower relative dominance; J9144 (22.5K claims) ranks #40 of 615 providers (94th percentile; notably above typical national volume) and J9299 (37K claims) ranks #40 of 505 providers (92th percentile; notably above typical national volume). The practice also posts strong rankings on biosimilars such as Q5115 ($297.2K, rank #3 of 79, 97th percentile) and Q5107 ($169.1K, rank #7 of 78, 92th percentile), indicating significant uptake of biosimilar agents.

Procedural throughput and infusion capacity: High procedural and administration code volumes and ranks — e.g., 96413 at $209.4K (3.1%) ranks #5 of 7514 providers (100th percentile; extreme outlier), 96417 at $37.7K ranks #2 of 3014 (100th percentile; extreme outlier), and 96375 at $24.6K ranks #39 of 5191 (99th percentile; extreme outlier) — point to substantial infusion throughput and established workflows for multi‑agent chemotherapy sessions.

Supportive care mix: The provider bills meaningful volumes for supportive agents and blood products (for example, J1561 $426K, 6.2% of Medicare revenue; J0897 $407.2K, 6.0%; Q5111 $152.8K, 2.2%; P9016 $15K, 0.2%), signaling that the practice manages both primary oncologic therapy and its ancillary supportive care needs on site. These items, often reimbursed at lower unit prices but high claim counts, complement the high‑value oncology drugs in the revenue mix.

Tenure and business implication: The provider’s NPI was enumerated on 2007-02-15 (~19 years ago), indicating long tenure. Combined with persistent high national ranks and concentrated Medicare revenue, this suggests an established oncology practice with a Medicare‑centric revenue base and limited Medicaid engagement in the available data.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

63 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	67,600	$40	$2.7M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	22,500	$40	$855K
J9299	Injection, nivolumab, 1 mg	37,020	$20	$777.5K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	11,210	$40	$426K
J0897	Injection, denosumab, 1 mg	22,620	$20	$407.2K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	8,740	$30	$297.2K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	27,900	$10	$279K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,870	$110	$209.4K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	7,350	$20	$169.1K
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg	1,430	$110	$152.8K

Showing 1–10 of 63

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 63 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Maryland Distribution

Mei Tang — 11 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Maryland

Full comparison — all codes billed, vs. state median

63 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	2	60	15,000	$40	$787.6K
J9299	4	20	24,080	$20	$660.6K
J9144	4	30	11,970	$40	$493.5K
J1561	1	10	11,210	$40	$427.9K
J9264	1	10	27,900	$10	$273.2K
Q5115	1	10	3,300	$30	$170.1K
J0897	16	340	3,600	$20	$114.4K
Q5117	1	10	4,390	$20	$99.4K
Q5111	2	10	930	$110	$92.7K
Q5107	1	10	2,770	$20	$82.3K

Showing 1–10 of 63

Related Providers

Other providers that share a Tax Identification Number (TIN) with Mei Tang, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Greater Baltimore Medical Center, Inc.	MD	General Practice Physician	$0	$9.4M
Paul Celano	MD	Medical Oncology Physician	$1.3M	$0
Geoffrey Neuner	MD	Radiation Oncology Physician	$1.1M	$0
Dongyan Liu	MD	Hematology & Oncology Physician	$1.1M	$0
Scott London	MD	Otolaryngology Physician	$493.8K	$0
Kruti Patel	MD	Radiation Oncology Physician	$458.7K	$0
Douglas Mccorkle	MD	Otolaryngology Physician	$413.2K	$5.5K
Daniel Bregman	TN	Ophthalmology Physician	$416.9K	$0
David Buchalter	MD	Orthopaedic Surgery Physician	$339.1K	$0
James Porterfield	MD	Cardiovascular Disease Physician	$310.5K	$0

Nearby Providers

Other providers in the same ZIP code as Mei Tang, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Baltimore County Public Schools	MD	Local Education Agency (LEA)	$0	$102.7M
Gilchrist Hospice Care Inc.	MD	Inpatient Hospice	$0	$60.7M
Sheppard Pratt Physicians, P.A.	MD	Psychiatry Physician	$0	$17.3M
Patient First Maryland Medical Group PLLC	MD	Family Medicine Physician	$0	$6.8M
University Of Maryland St. Joseph Medical Group, LLC	MD	General Practice Physician	$0	$6.2M
Sheppard Pratt Physicians PA	MD	Mental Health Counselor	$0	$5.7M
Baltimore County Deparment Of Health	MD	Public Health or Welfare Agency	$0	$5.2M
David Baranano	MD	Ophthalmology Physician	$4.2M	$0
Raymond Sjaarda	MD	Ophthalmology Physician	$4.2M	$0
John Thompson	MD	Ophthalmology Physician	$3.9M	$0

Mei Tang — Billing Profile & Reimbursement Data

Sign up for Mei Tang — Billing Profile & Reimbursement Data policy alerts

Mei Tang — Billing Profile & Reimbursement Data

Sign up for Mei Tang — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References